BMO Capital analyst Etzer Darout downgraded ImmunoGen (IMGN) to Market Perform from Outperform with a price target of $31, up from $26, after the company agreed to be acquired by AbbVie (ABBV) for $31.26 per share in cash. The firm sees low ImmunoGen pipeline risks in terms of the deal closing given that the pre-deal price implied little pipeline credit and it expects Elahere to continue to meet or exceed sales expectations in the near term.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMGN: